Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models

PURPOSE: Checkpoint kinase 1 (CHK1) inhibitors potentiate the DNA damaging effects of cytotoxic therapies and/or promote elevated levels of replication stress, leading to tumor cell death. Prexasertib (LY2606368) is a CHK1 small molecule inhibitor under clinical evaluation in multiple adult and pedi...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: Lowery, Caitlin D., Dowless, Michele, Renschler, Matthew, Blosser, Wayne, VanWye, Alle B., Stephens, Jennifer R., Iversen, Philip W., Lin, Aimee Bence, Beckmann, Richard P., Krytska, Kateryna, Cole, Kristina A., Maris, John M., Hawkins, Douglas S., Rubin, Brian P., Kurmasheva, Raushan T., Houghton, Peter J., Gorlick, Richard, Kolb, E. Anders, Kang, Min H., Reynolds, C. Patrick, Erickson, Stephen W., Teicher, Beverly A., Smith, Malcolm A., Stancato, Louis F.
Format: Artigo
Langue:Inglês
Publié: 2018
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6445779/
https://ncbi.nlm.nih.gov/pubmed/30563935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-2728
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires